MedTrace Logo

Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot

NCT06184373 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2026-01-22

No results posted yet for this study

Summary

One third of women with gestational diabetes (GDM), diabetes diagnosed during pregnancy, have abnormal glucose levels within 3 years after pregnancy, but follow up is low. Continuous glucose monitors (CGM), a small sensor inserted under the skin, may be able to screen women with GDM for diabetes risk. The investigators will ask postpartum women to use CGM at 6-8 weeks postpartum and answer surveys about quality of life after wearing the CGM. The investigators will collect data on blood glucose trends for future studies if participants find CGM use acceptable. The investigators hope to learn if CGM could improve postpartum follow up experiences for people with recent GDM.

Conditions

Interventions

DEVICE

Continuous glucose monitor

CGMs will be worn for a maximum of 10 days at 6-8 weeks postpartum.

DIAGNOSTIC_TEST

Oral Glucose Tolerance Test

At 10-12 weeks postpartum, participants will complete an oral glucose tolerance test, which involves drinking a glucose substance and having glucose levels measured a maximum of 3 times.

DIAGNOSTIC_TEST

Hemoglobin A1c

At 11-14 months postpartum, participants will be asked to have their blood drawn to check their hemoglobin A1c to look for signs of developed insulin resistance

Sponsors & Collaborators

  • DexCom, Inc.

    collaborator INDUSTRY

  • Ohio State University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-06
Primary Completion
2026-05-30
Completion
2027-05-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06184373 on ClinicalTrials.gov